細菌性膣炎薬の世界市場2020-2026:Rx、OTC

QYResearchが発行した調査報告書(QYR20AP00249)
◆英語タイトル:Global Bacterial Vaginosis Drug Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP00249
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:140
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、細菌性膣炎薬の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、細菌性膣炎薬のグローバル市場動向、メーカー別競争状況、種類別市場規模(Rx、OTC)、用途別市場規模(病院、薬局、その他)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・細菌性膣炎薬の種類別市場2015-2026:Rx、OTC
・細菌性膣炎薬の用途別市場2015-2026:病院、薬局、その他
・細菌性膣炎薬の北米市場分析
・細菌性膣炎薬のアジア市場分析
・細菌性膣炎薬の中南米市場分析
・細菌性膣炎薬の中東・アフリカ市場分析
・関連企業情報:Bayer、Pfizer、Sanofi、Piramal、Abbott、Galderma、Mission、Alkem、Xiuzheng、Teva、Perrigo、West-Ward、HPGC、Yunnan Baiyao、Starpharma、Novel、Edenvridge
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.The classification of bacterial vaginosis drug includes Rx and OTC, and the proportion of OTC in 2016 is about 72%.

Bacterial vaginosis drug is widely sold in hospital, pharmacy and other field. The most proportion of bacterial vaginosis drug is sold in pharmacy, and the revenue in 2016 is about 423 M USD.

USA region is the largest supplier of bacterial vaginosis drug, with a revenue market share nearly 32% in 2016. Europe is the second largest supplier of Bacterial Vaginosis Drug, enjoying revenue market share nearly 30% in 2016.

USA and Europe are the largest consumption places, with the consumption market share nearly 28% in 2016.

Market competition is intense. Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
In 2019, the global Bacterial Vaginosis Drug market size was US$ 858.4 million and is forecast to US$ 1072.8 million in 2026, growing at a CAGR of 3.2% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Bacterial Vaginosis Drug.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Bacterial Vaginosis Drug market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Bacterial Vaginosis Drug market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Bacterial Vaginosis Drug market. Readers of the report can become informed about current and future trends of the global Bacterial Vaginosis Drug market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Bacterial Vaginosis Drug markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Bacterial Vaginosis Drug market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Bacterial Vaginosis Drug market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Bacterial Vaginosis Drug market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Bacterial Vaginosis Drug market is segmented into
Rx
OTC

Market Segment by Application, the Bacterial Vaginosis Drug market is segmented into
Hospital
Pharmacy
Other

This report includes the following manufacturers; we can also add the other companies as you want.
Bayer
Pfizer
Sanofi
Piramal
Abbott
Galderma
Mission
Alkem
Xiuzheng
Teva
Perrigo
West-Ward
HPGC
Yunnan Baiyao
Starpharma
Novel
Edenvridge

The study objectives are:
To analyze and research the global Bacterial Vaginosis Drug status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Bacterial Vaginosis Drug manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Bacterial Vaginosis Drug are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Bacterial Vaginosis Drug Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Bacterial Vaginosis Drug Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Rx
1.3.3 OTC
1.4 Market Segment by Application
1.4.1 Global Bacterial Vaginosis Drug Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hospital
1.4.3 Pharmacy
1.4.4 Other
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Bacterial Vaginosis Drug Revenue (2015-2026)
2.1.1 Global Bacterial Vaginosis Drug Revenue (2015-2026)
2.1.2 Global Bacterial Vaginosis Drug Sales (2015-2026)
2.2 Bacterial Vaginosis Drug Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Bacterial Vaginosis Drug Sales by Regions (2015-2020)
2.2.2 Global Bacterial Vaginosis Drug Revenue by Regions (2015-2020)
2.3 Global Top Bacterial Vaginosis Drug Regions (Countries) Ranking by Market Size
2.4 Bacterial Vaginosis Drug Industry Trends
2.4.1 Bacterial Vaginosis Drug Market Top Trends
2.4.2 Market Drivers
2.4.3 Bacterial Vaginosis Drug Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Bacterial Vaginosis Drug Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Bacterial Vaginosis Drug Manufacturers by Sales (2015-2020)
3.1.1 Global Bacterial Vaginosis Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Bacterial Vaginosis Drug Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Bacterial Vaginosis Drug Sales in 2019
3.2 Global Top Manufacturers Bacterial Vaginosis Drug by Revenue
3.2.1 Global Bacterial Vaginosis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Bacterial Vaginosis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Bacterial Vaginosis Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bacterial Vaginosis Drug as of 2019)
3.4 Global Bacterial Vaginosis Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Bacterial Vaginosis Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Bacterial Vaginosis Drug Market
3.7 Key Manufacturers Bacterial Vaginosis Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Bacterial Vaginosis Drug Historic Market Review by Type (2015-2020)
4.1.2 Global Bacterial Vaginosis Drug Sales Market Share by Type (2015-2020)
4.1.3 Global Bacterial Vaginosis Drug Revenue Market Share by Type (2015-2020)
4.1.4 Bacterial Vaginosis Drug Price by Type (2015-2020)
4.1 Global Bacterial Vaginosis Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Bacterial Vaginosis Drug Sales Forecast by Type (2021-2026)
4.2.3 Global Bacterial Vaginosis Drug Revenue Forecast by Type (2021-2026)
4.2.4 Bacterial Vaginosis Drug Price Forecast by Type (2021-2026)

5 Global Bacterial Vaginosis Drug Market Size by Application
5.1 Global Bacterial Vaginosis Drug Historic Market Review by Application (2015-2020)
5.1.2 Global Bacterial Vaginosis Drug Sales Market Share by Application (2015-2020)
5.1.3 Global Bacterial Vaginosis Drug Revenue Market Share by Application (2015-2020)
5.1.4 Bacterial Vaginosis Drug Price by Application (2015-2020)
5.2 Global Bacterial Vaginosis Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Bacterial Vaginosis Drug Sales Forecast by Application (2021-2026)
5.2.3 Global Bacterial Vaginosis Drug Revenue Forecast by Application (2021-2026)
5.2.4 Bacterial Vaginosis Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Bacterial Vaginosis Drug Breakdown Data by Company
6.2 North America Bacterial Vaginosis Drug Breakdown Data by Type
6.3 North America Bacterial Vaginosis Drug Breakdown Data by Application
6.4 North America Bacterial Vaginosis Drug Breakdown Data by Countries
6.4.1 North America Bacterial Vaginosis Drug Sales by Countries
6.4.2 North America Bacterial Vaginosis Drug Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Bacterial Vaginosis Drug Breakdown Data by Company
7.2 Europe Bacterial Vaginosis Drug Breakdown Data by Type
7.3 Europe Bacterial Vaginosis Drug Breakdown Data by Application
7.4 Europe Bacterial Vaginosis Drug Breakdown Data by Countries
7.4.1 Europe Bacterial Vaginosis Drug Sales by Countries
7.4.2 Europe Bacterial Vaginosis Drug Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Bacterial Vaginosis Drug Breakdown Data by Company
8.2 Asia Pacific Bacterial Vaginosis Drug Breakdown Data by Type
8.3 Asia Pacific Bacterial Vaginosis Drug Breakdown Data by Application
8.4 Asia Pacific Bacterial Vaginosis Drug Breakdown Data by Regions
8.4.1 Asia Pacific Bacterial Vaginosis Drug Sales by Regions
8.4.2 Asia Pacific Bacterial Vaginosis Drug Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Bacterial Vaginosis Drug Breakdown Data by Company
9.2 Latin America Bacterial Vaginosis Drug Breakdown Data by Type
9.3 Latin America Bacterial Vaginosis Drug Breakdown Data by Application
9.4 Latin America Bacterial Vaginosis Drug Breakdown Data by Countries
9.4.1 Latin America Bacterial Vaginosis Drug Sales by Countries
9.4.2 Latin America Bacterial Vaginosis Drug Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Bacterial Vaginosis Drug Breakdown Data by Type
10.2 Middle East and Africa Bacterial Vaginosis Drug Breakdown Data by Application
10.3 Middle East and Africa Bacterial Vaginosis Drug Breakdown Data by Countries
10.3.1 Middle East and Africa Bacterial Vaginosis Drug Sales by Countries
10.3.2 Middle East and Africa Bacterial Vaginosis Drug Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Bayer Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Bayer Bacterial Vaginosis Drug Products and Services
11.1.5 Bayer SWOT Analysis
11.1.6 Bayer Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Pfizer Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Pfizer Bacterial Vaginosis Drug Products and Services
11.2.5 Pfizer SWOT Analysis
11.2.6 Pfizer Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Sanofi Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Sanofi Bacterial Vaginosis Drug Products and Services
11.3.5 Sanofi SWOT Analysis
11.3.6 Sanofi Recent Developments
11.4 Piramal
11.4.1 Piramal Corporation Information
11.4.2 Piramal Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Piramal Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Piramal Bacterial Vaginosis Drug Products and Services
11.4.5 Piramal SWOT Analysis
11.4.6 Piramal Recent Developments
11.5 Abbott
11.5.1 Abbott Corporation Information
11.5.2 Abbott Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Abbott Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Abbott Bacterial Vaginosis Drug Products and Services
11.5.5 Abbott SWOT Analysis
11.5.6 Abbott Recent Developments
11.6 Galderma
11.6.1 Galderma Corporation Information
11.6.2 Galderma Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Galderma Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Galderma Bacterial Vaginosis Drug Products and Services
11.6.5 Galderma SWOT Analysis
11.6.6 Galderma Recent Developments
11.7 Mission
11.7.1 Mission Corporation Information
11.7.2 Mission Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Mission Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Mission Bacterial Vaginosis Drug Products and Services
11.7.5 Mission SWOT Analysis
11.7.6 Mission Recent Developments
11.8 Alkem
11.8.1 Alkem Corporation Information
11.8.2 Alkem Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Alkem Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Alkem Bacterial Vaginosis Drug Products and Services
11.8.5 Alkem SWOT Analysis
11.8.6 Alkem Recent Developments
11.9 Xiuzheng
11.9.1 Xiuzheng Corporation Information
11.9.2 Xiuzheng Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Xiuzheng Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Xiuzheng Bacterial Vaginosis Drug Products and Services
11.9.5 Xiuzheng SWOT Analysis
11.9.6 Xiuzheng Recent Developments
11.10 Teva
11.10.1 Teva Corporation Information
11.10.2 Teva Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Teva Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Teva Bacterial Vaginosis Drug Products and Services
11.10.5 Teva SWOT Analysis
11.10.6 Teva Recent Developments
11.11 Perrigo
11.11.1 Perrigo Corporation Information
11.11.2 Perrigo Business Overview and Total Revenue (2019 VS 2018)
11.11.3 Perrigo Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 Perrigo Bacterial Vaginosis Drug Products and Services
11.11.5 Perrigo SWOT Analysis
11.11.6 Perrigo Recent Developments
11.12 West-Ward
11.12.1 West-Ward Corporation Information
11.12.2 West-Ward Business Overview and Total Revenue (2019 VS 2018)
11.12.3 West-Ward Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 West-Ward Bacterial Vaginosis Drug Products and Services
11.12.5 West-Ward SWOT Analysis
11.12.6 West-Ward Recent Developments
11.13 HPGC
11.13.1 HPGC Corporation Information
11.13.2 HPGC Business Overview and Total Revenue (2019 VS 2018)
11.13.3 HPGC Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 HPGC Bacterial Vaginosis Drug Products and Services
11.13.5 HPGC SWOT Analysis
11.13.6 HPGC Recent Developments
11.14 Yunnan Baiyao
11.14.1 Yunnan Baiyao Corporation Information
11.14.2 Yunnan Baiyao Business Overview and Total Revenue (2019 VS 2018)
11.14.3 Yunnan Baiyao Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.14.4 Yunnan Baiyao Bacterial Vaginosis Drug Products and Services
11.14.5 Yunnan Baiyao SWOT Analysis
11.14.6 Yunnan Baiyao Recent Developments
11.15 Starpharma
11.15.1 Starpharma Corporation Information
11.15.2 Starpharma Business Overview and Total Revenue (2019 VS 2018)
11.15.3 Starpharma Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.15.4 Starpharma Bacterial Vaginosis Drug Products and Services
11.15.5 Starpharma SWOT Analysis
11.15.6 Starpharma Recent Developments
11.16 Novel
11.16.1 Novel Corporation Information
11.16.2 Novel Business Overview and Total Revenue (2019 VS 2018)
11.16.3 Novel Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.16.4 Novel Bacterial Vaginosis Drug Products and Services
11.16.5 Novel SWOT Analysis
11.16.6 Novel Recent Developments
11.17 Edenvridge
11.17.1 Edenvridge Corporation Information
11.17.2 Edenvridge Business Overview and Total Revenue (2019 VS 2018)
11.17.3 Edenvridge Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.17.4 Edenvridge Bacterial Vaginosis Drug Products and Services
11.17.5 Edenvridge SWOT Analysis
11.17.6 Edenvridge Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Bacterial Vaginosis Drug Sales Channels
12.2.2 Bacterial Vaginosis Drug Distributors
12.3 Bacterial Vaginosis Drug Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.1.1 Global Bacterial Vaginosis Drug Sales Forecast by Regions (2021-2026)
13.1.2 Global Bacterial Vaginosis Drug Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.2.2 North America Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.2.3 North America Bacterial Vaginosis Drug Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.3.2 Europe Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.3.3 Europe Bacterial Vaginosis Drug Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.4.2 Asia Pacific Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Bacterial Vaginosis Drug Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.5.2 Latin America Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.5.3 Latin America Bacterial Vaginosis Drug Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Bacterial Vaginosis Drug Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Bayer、Pfizer、Sanofi、Piramal、Abbott、Galderma、Mission、Alkem、Xiuzheng、Teva、Perrigo、West-Ward、HPGC、Yunnan Baiyao、Starpharma、Novel、Edenvridge

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 細菌性膣炎薬の世界市場2020-2026:Rx、OTC(Global Bacterial Vaginosis Drug Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。